TSO500 Tissue / TruSight Oncology 500 Comprehensive Assay​

TruSight Oncology 500 Tissue
(TSO500 Tissue)

Pan-cancer next-generation sequencing assay for biomarker identification and comprehensive genomic profiling across 523 genes

Pan-Cancer Comprehensive Genomic Profiling of Solid Tumors​

Gain an expansive view of your solid tumor samples by targeting 523 cancer-related genes using the TruSight Oncology 500 tissue. Not only does this assay identify all relevant variants (SNVs, insertions, deletions, CNVs, gene fusions, and transcript variants) across various tumor types, but it also reports tumor mutational burden (TMB) score and microsatellite instability (MSI) status.


Our comprehensive genomic panel has advantages over individual biomarker assays in its ability to detect multiple biomarkers with one test, saving time, money, and samples. Q2 can meet your profiling needs by leveraging trusted technology from Illumina® in combination with our global laboratory network and expert support team.

TSO500 Tissue / TSO500 Comprehensive

An Efficient, Reliable Solution for Tumor Characterization

Minimal input, extensive results

Obtain full exon coverage of 522 genes using as little as 40ng of FFPE DNA and RNA input.

Measurement of key immuno-oncology biomarkers

Gain insight into TMB score and MSI status in addition to variant calls. TruSight Oncology 500 can reproducibly assess TMB and reliably determine TMB-H, making it a competitive offering for TMB assessment.

Confident variant detection

Obtain a high-resolution view of variants enabled by TSO500’s hybrid-capture chemistry and unique molecular indices.

Simple, cost-effective workflow

Detect multiple biomarkers with a single assay to save time, money, and samples.

Expansive services enabled by our global network

Our centralized scientific operational oversight combined with our global laboratory footprint enables comprehensive, large-scale trial support. We enable clinical development support irrespective of geography.

Flexible customization to satisfy specific needs

We work with you to understand your specific needs, and our team provides cost-effective recommendations from custom assay development to specialized bioinformatics support.

Comprehensive Panel Content​

The TruSight Oncology 500 Tissue (TSO500 Tissue) can detect:


Mb of DNA



kb of RNA



Microsatellite Instability Sites​



Tumor Mutational Burden Genes



RNA Splice Variant Genes



Small Variants (SNVs & Indels) Genes



Copy Number Variant Genes​



RNA Fusions Genes


Assay Comparison



Request a Quote

Supporting Studies Around the World

Our centralized, scientific, and operational oversight combined with our global laboratory footprint enables comprehensive, large-scale trial support. You will be supported every step of the way by our scientific project management team who will work with you to understand the most cost-effective recommendations to meet your specific needs. We are committed to transparency so you can feel confident in our promises of quality and timely delivery. We can expert support team can meet your research needs from nearly anywhere in the world with our genomic centers in the United States, China, United Kingdom, and Singapore.



Simplify Your Work



Request a Quote

Request a quote today to discover how TSO500 with
Q2 Solutions can advance your research.

Ship Samples​

Ship your samples to one of our global genomic laboratory centers.​

Get Results

Obtain in-depth data revealing insights into your solid tumor samples.

Request a Quote

Related Thought Leaders Insights

TruSight Oncology 500 (TSO500) Tissue Assay

The TruSight Oncology 500 (TSO500) for tissue assay employs a hybrid capture-based approach targeting 523 genes and leverages unique molecular indices to enable detection of low allele frequency...

Panel-based tumor mutational burden (TMB) analysis of matched tumor and plasma specimens using Illumina’s TruSight Oncology 500 next-generation sequencing assay

Checkpoint inhibitor (CPI) therapy demonstrates a remarkable clinical benefit in many cancer types. However, the ability to successfully select patients who will benefit from CPIs is still limited....

TMB Standardization by Alignment to Reference Standards

At ASCO 2019, we presented a poster with Friends of Cancer Research (FOCR), highlighting their Tumor Mutational Burden (TMB) Harmonization Project. The goal of this Project is to harmonize TMB...